Radiopharm Theranostics RADX
NASDAQ RADX
$1.44 -0.18 (-11.11%)
As of: Oct 1, 2026 · 10:36 AM EDT

Radiopharm Theranostics (RADX) Total Non-Current Liabilities (2024 - 2026)

Updated

Radiopharm Theranostics (RADX) reported Total Non-Current Liabilities of $134,159 for fiscal Q4 2026 (quarter ended Jun 30, 2026), down 27.0% from $183,657 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Radiopharm Theranostics posted Total Non-Current Liabilities of $128,449, down 99.6% from FY2025.

  • By fiscal year, Total Non-Current Liabilities came in at $28.68 million in FY2025 (+5.8%) and $27.11 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 105.99 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 106.45 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 80.25 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -967.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 81.11 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 36.04 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 100.86 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 5.92 Bn
10 Radiopharm Theranostics 5.74 Bn 5.70 Bn 186,835.86 134,159.49
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 134,159.49
Jun 30, 2025 183,656.95
Dec 31, 2024 27.30 Mn
Jun 30, 2024 178,643.67
API Access

Radiopharm Theranostics Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=RADX&period=max&api_key=YOUR_API_KEY